Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Is the Essential Thrombocythemia (ET) Market Size Expected to Evolve From 2025 to 2029?
The essential thrombocythemia (et) market size has grown strongly in recent years. It will grow from $0.83 billion in 2024 to $0.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising cases of essential thrombocythemia, rising cases of sickle cell anemia, increasing investment in research and development, growing awareness among healthcare professionals, and increasing popularity of drugs.
The essential thrombocythemia (et) market size is expected to see strong growth in the next few years. It will grow to " $1.1 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising awareness and early diagnosis of essential thrombocythemia, increasing availability of hematology testing, a growing geriatric population, increasing healthcare expenditure, and rising federal funding. Major trends in the forecast period include technological advancements, genetic profiling, novel targeted therapies, advancements in telemedicine, and strategic collaboration.
Get your free report sample today:
Which Primary Drivers Are Expected to Shape the Future of the Essential Thrombocythemia (ET) Market?
The growing adoption of personalized medicine is expected to propel the growth of the essential thrombocythemia (ET) market going forward. Personalized medicine refers to a medical approach that customizes treatment and prevention strategies based on an individual's genetic makeup, lifestyle, and environmental factors. Personalized medicine adoption is increasing due to advancements in genomics, biotechnology, and data analytics, enabling more precise diagnostics and targeted therapies. Personalized medicine helps in essential thrombocythemia by enabling targeted therapies based on genetic mutations, improving treatment precision and patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the essential thrombocythemia (ET) market.
How Is the Essential Thrombocythemia (ET) Market Categorized Based on Key Segments?
The essential thrombocythemia (et)market covered in this report is segmented –
1) By Treatment Type: Interferon; Anagrelide; Hydroxyurea; Aspirin
2) By Diagnosis: Blood Tests; Bone Marrow Biopsy; Gene Mutation Analysis; Other Diagnosis
3) By End User: Hospitals; Research Organizations; Specialty Clinics
Subsegments:
1) By Interferon: Pegylated Interferon; Standard Interferon; Combination Therapy
2) By Anagrelide: Monotherapy; Combination With Aspirin; Dose-Adjusted Therapy
3) By Hydroxyurea: Low-Dose Therapy; High-Dose Therapy; Combination With Antiplatelet Agents
4) By Aspirin: Low-Dose Aspirin; High-Dose Aspirin; Combination With Cytoreductive Therapy
Which Emerging Trends Are Shaping the Future of the Essential Thrombocythemia (ET) Market?
Major companies operating in the essential thrombocythemia (ET) market are prioritizing novel therapeutics, such as Phase 3 clinical trials for bomedemstat, to enhance treatment efficacy, improve patient outcomes, and expand available therapeutic options. These late-stage trials evaluate bomedemstat, an LSD1 inhibitor, for its safety and effectiveness in patients requiring advanced treatment solutions. For instance, in August 2024, Merck & Co. Inc., a US-based pharmaceutical company, announced the initiation of Shorespan-007, a Phase 3 clinical trial evaluating bomedemstat, an investigational LSD1 inhibitor, for the treatment of essential thrombocythemia (ET). The trial focuses on patients who have not previously received cytoreductive therapy. Global recruitment for Shorespan-007 has commenced, with patient enrollment now underway.
Who Are the Established and Emerging Companies Competing in the Essential Thrombocythemia (ET) Market?
Major companies operating in the essential thrombocythemia (ET) market are Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Bayer AG, Bristol Myers Squibb Company, Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Fresenius Kabi AG, Incyte Corporation, Vifor Pharma Management AG, Bio-Techne Corporation, Argenx SE, AOP Orphan Pharmaceuticals AG, Orchard Therapeutics plc, Medunik USA., Kartos Therapeutics Inc.
Get the detailed essential thrombocythemia (et) market report today
Which Region Is Expected to Dominate the Essential Thrombocythemia (ET) Market During the Forecast Period?
North America was the largest region in the essential thrombocythemia (ET) market in 2024. The regions covered in the essential thrombocythemia (ET) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment